SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Maroney Marcee

(Last) (First) (Middle)
C/O CARBYLAN THERAPEUTICS, INC.
3181 PORTER DRIVE

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/08/2015
3. Issuer Name and Ticker or Trading Symbol
Carbylan Therapeutics, Inc. [ CBYL ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) 11/23/2014 06/06/2023 Common Stock 18,750 0.56 D
Stock Option (Right to Buy) 02/01/2011 02/03/2016 Common Stock 23,432 0.8 D
Stock Option (Right to Buy) 01/07/2011 12/15/2016 Common Stock 1,000 0.8 D
Stock Option (Right to Buy) 05/16/2012 05/16/2018 Common Stock 50,000 1.2 D
Stock Option (Right to Buy) 03/31/2013 12/11/2019 Common Stock 14,500 0.96 D
Stock Option (Right to Buy) (1) 03/05/2023 Common Stock 36,289 0.56 D
Stock Option (Right to Buy) (2) 06/06/2023 Common Stock 10,250 0.56 D
Stock Option (Right to Buy) (3) 10/31/2024 Common Stock 20,000 7 D
Explanation of Responses:
1. The shares subject to the option shall vest with respect to 50% of such shares at the rate of 1/48th of such shares per month on each monthly anniversary following December 7, 2012, provided that the holder is still an employee or consultant of the Issuer as of such date. The remaining 50% of the shares subject to the option shall start vesting at the rate of 1/48th per month on each monthly anniversary following September 30, 2014, provided that the holder is an employee or consultant of the Issuer as of such date. 12,852 shares subject to the option are vested and exercisable as of April 8, 2015. The remaining 23,437 shares subject to the option shall vest as discussed herein.
2. 4,697 shares subject to the option are vested and exercisable as of April 8, 2015. The remaining 5,553 shares subject to the option shall vest monthly until June 6, 2017.
3. 2,083 shares subject to the option are vested and exercisable as of April 8, 2015. The remaining 17,917 shares subject to the option shall vest monthly until November 1, 2018.
Remarks:
Vice President, Clinical Affairs Exhibit List Exhibit 24 - Limited Power of Attorney
By: /s/ David J. Saul, Attorney-in-Fact 04/08/2015
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
         LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

  Know all by these presents, that the undersigned hereby makes,constitutes
and appoints each of David M. Renzi, T. Michael White, and David J.Saul signing
singly and each acting individually, as the undersigned's true and lawful
attorney-in-fact with full power and authority as hereinafter described to:

        (1)  execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director and/or stockholder of Carbylan
Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments
thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder (the "Exchange Act");

        (2)  do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to prepare, complete and execute
any such Form 3, 4, or 5, prepare, complete and execute any amendment or
amendments thereto, and timely deliver and file such form with the United States
Securities and Exchange Commission (the "SEC") and any stock exchange or similar
authority, including without limitation the filing of a Form ID or any other
application materials to enable the undersigned to gain or maintain access to
the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

        (3)  seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information regarding transactions in the Company's
securities from any third party, including brokers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
person to release any such information to such attorney-in-fact and approves and
ratifies any such release of information; and

        (4)  take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

  The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming nor
relieving, nor is the Company assuming nor relieving, any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act. The undersigned
acknowledges that neither the Company nor the foregoing attorneys-in-fact assume
(i) any liability for the undersigned's responsibility to comply with the
requirement of the Exchange Act, (ii) any liability of the undersigned for any
failure to comply with such requirements, or (iii) any obligation or liability
of the undersigned for profit disgorgement under Section 16(b) of the Exchange
Act.

  This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

  IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 20th day of January, 2015.

                                        /s/ Marcee M. Maroney
                                        ----------------------------------------
                                        Signature

                                        Marcee M. Maroney
                                        ----------------------------------------
                                        Print Name